Skip to content

Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer

Document Type
Publications · Journal Article
Registered DB
KCISCIEScopus
Journal Ranking
JCR Q2Scopus Q1KCI Q1
Journal
Cancer Research and Treatment58(2) · pp.591 · 2026
Citation
Web of Science 1Scopus 1KCI 0
FWCI (Scopus)
1.83
JCR IF
JCR 2024 3.8
ISSN
1598-2998

Authors

  1. Lee, Hye WonFirst authorSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
  2. Jung, Eui HyunNatl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea
  3. Kim, Kyung HwanPusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
  4. Ha, Hong-kooPusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
  5. Oh, Jong JinSeoul Natl Univ, Bundang Hosp, Dept Urol, Coll Med, Seongnam, South Korea
  6. Kang, Seok HoKorea Univ, Coll Med, Dept Urol, Anam Hosp, Seoul, South Korea
  7. Jeong, Seung-hwanSeoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
  8. Yuk, Hyeong DongSeoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
  9. Heo, Ji EunYonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
  10. Ham, Won SikYonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
  11. Hwang, Eu ChangChonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
  12. Il Jung, SeungChonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
  13. Song, WanSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
  14. Lim, BumjinUniv Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
  15. Hong, BumsikUniv Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
  16. Jeong, Byung ChangSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
  17. Seo, Ho KyungCorresponding authorNatl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea

Abstract

PurposeThis study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC).Materials and MethodsThis retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models.ResultsPatients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course.ConclusionOur research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability.

Keywords

TherapeuticsNon-muscle invasive bladder neoplasmsBacillus Calmette–GuérinFailureOrganization and administrationIntravesical administrationGemcitabineOrgan preservation

Identifiers

Scopus EID
2-s2.0-105035841246
WoS UID
001743756600021
KCI
ART003325921